BPH - Enlarged Prostate Treatment

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial ...

Men with low level PSA receive aggressive treatment
Controversy has long existed over the benefit of the prostate specific antigen (PSA) test used to screen for the presence of prostate cancer, and there has been little study to document the risk profile of men who have a PSA level at or below what is considered 'normal.' New research published in the latest edition of Archives of Internal Medicine (Vol. 170, No. 14) by a team of investigators at ...

Singular Research Initiates Coverage of Nymox With "Buy" Rating
HASBROUCK HEIGHTS, N.J. -- Singular Research has initiated coverage of Nymox Pharmaceutical Corporation with a "Buy" rating and a 12 month target price of $11.00. The report was written by Gregory P.

Sun Pharma announces US nod for generic Flomax
New Delhi, Jul 15 : Sun Pharmaceutical Industries Ltd today announced the approval of the US health regulator to market a generic version of Flomax tamsulosin capsules, used for treating enlarged prostate.

Sun Pharma gets USFDA nod for Flomax's generic version
Sun Pharmaceutical Industries today said that it has received the US health regulator's nod to market a generic version of Flomax tamsulosin capsules, used for treating enlarged prostate, in the American market.

New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit The Enzyme Linked To ...
A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH). BPH, also known as an enlarged prostate, is the most common benign proliferative disorder in men, affecting more than ...

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study
A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.